从基金十大重仓股角度 数据显示，招商基金旗下1只基金重仓诚意药业。招商和悦稳健养老一年持有期混合(FOF)A（006861） 二季度减持5.65万股，持有股数50.87万股，占基金净值比例为0.46%，位居第五大重仓股。根据测算， 今日浮盈赚取约32.05万元。 截至发稿，章鸽武累计任职时间6年175天，现任基金资产总规模15.83亿元，任职期间最佳基金回报 42.84%， 任职期间最差基金回报-34.2%。 10月15日，诚意药业涨5.1%，截至发稿，报12.99元/股，成交7838.12万元，换手率1.89%，总市值42.52 亿元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，浙江诚意药业股份有限公司位于上海市闵行区申虹路988弄富力悦都20幢9号7层，成立日期 2001年6月22日，上市日期2017年3月15日，公司主营业务涉及化学药品原料药及制剂的研发、生产和销 售。主营业务收入构成为：制剂80.99%，原料药17.46%，中药0.63%，中间体及 ...

Core Viewpoint - Chengyi Pharmaceutical's stock price has shown significant volatility, with a year-to-date increase of 78.88% but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 24, Chengyi Pharmaceutical's stock price rose by 2.06% to 13.38 CNY per share, with a market capitalization of 4.379 billion CNY [1] - The stock has experienced a decline of 2.97% over the last five trading days and 5.77% over the last twenty trading days, while it increased by 28.04% over the last sixty days [2] - The company has appeared on the trading leaderboard four times this year, with the most recent instance on August 6, where it recorded a net buy of 138 million CNY [2] Group 2: Financial Performance - For the first half of 2025, Chengyi Pharmaceutical reported a revenue of 417 million CNY, representing a year-on-year growth of 17.11%, and a net profit attributable to shareholders of 112 million CNY, up 47.03% year-on-year [2] - The company has distributed a total of 474 million CNY in dividends since its A-share listing, with 203 million CNY distributed over the past three years [3] Group 3: Business Overview - Chengyi Pharmaceutical, established on June 22, 2001, and listed on March 15, 2017, is primarily engaged in the research, production, and sales of chemical pharmaceutical raw materials and formulations [2] - The revenue composition of the company includes 80.99% from formulations, 17.46% from raw materials, 0.63% from traditional Chinese medicine, and minor contributions from intermediates and food [2] - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including hepatitis treatment and pharmaceutical e-commerce [2]